CEMIC - Hospital Universitario Sede Saavedra - CABA, Buenos Aires

El Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno” (CEMIC) es una Asociación civil sin fines de lucro, entidad de bien público y universitaria. Nació en 1958 a partir de la visión innovadora del Dr. Norberto Quirno y de un grupo de discípulos comprometidos, que quisieron mejorar la medicina argentina. Esta visión ha convertido a esta institución en líder y referente en el área de la salud.
logoCEMIC - Hospital Universitario Sede Saavedra - CABA, Buenos Aires
Av. Galvan 4102, CABA, Buenos Aires
Select an option
Specializations
Esclerosis múltiple
Covid-19
Coronavirus
Cáncer
Enfermedad de Crohn
Influenza A
Linfoma
Lupus eritematoso sistémico
Lupus eritematoso sistémico
Melanoma
Pan Tumor
Poliquistosis renal autosómica dominante
Our team
Medical staff
Juan Ignacio Rojas
Stella Zarza
Nicolás Torresi
Pablo Bonvehí
Vanina Wainsztein
Nicolás Torressi
Alejandro Kuzminin
Aldo Perfetti
Diego Castro
Corina Capparelli
Victoria Marroquin
Florencia Perazzo
Gonzalo Recondo
Analia Patricia Alvarez
Máximo De la Vega
Pablo Olivera Sendra
Fernando Galanternik
Patricio José Duarte
Open studies
Breast Cancer
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy - Astefania - Hoffmann-La RocheSee more
A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. - VERITAC-2 - Arvinas Estrogen Receptor, Inc.See more
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer - Hoffmann-La RocheSee more
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) - MK-2870-012 - Merck Sharp & Dohme LLCSee more
Lung cancer
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection - ADAURA2 - AstraZenecaSee more
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer - KontRASt-02 - Novartis PharmaceuticalsSee more
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer - GlaxoSmithKlineSee more
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) - TRIDENT-3 - Zai Lab (Shanghai) Co., Ltd.See more
Leukemia
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) - MK-1026-003 - Merck Sharp & Dohme Corp.See more
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010) - BELLWAVE-010 - Merck Sharp & Dohme LLCSee more
Alzheimer disease
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease - PROGRESS-AD - GlaxoSmithKlineSee more
Bladder Cancer
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy - IMvigor011 - Hoffmann-La RocheSee more
Cardiovascular disease
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation - ZEUS - Novo Nordisk A/SSee more
Covid-19
Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19 Disease - CARR-COV-02 - Centro de Educación Medica e Investigaciones Clínicas Norberto QuirnoSee more
Endometrial Cancer
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) - MK-2870-005 - GOG FoundationSee more
Esophageal cancer
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. - FORTITUDE-102 - AmgenSee more
Gastric cancer
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. - FORTITUDE-102 - AmgenSee more
Gastroesophageal cancer
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. - FORTITUDE-102 - AmgenSee more
Graft versus Host Disease
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease. - ROCKnrol-1 - SanofiSee more
Lymphoma
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) - MK-1026-003 - Merck Sharp & Dohme Corp.See more
Multiple myeloma
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM - IRAKLIA - SanofiSee more
Non-Hodgkin Lymphoma
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010) - BELLWAVE-010 - Merck Sharp & Dohme LLCSee more
Rare diseases
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) - MK-1026-003 - Merck Sharp & Dohme Corp.See more
Renal disease
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation - ZEUS - Novo Nordisk A/SSee more
Ulcerative colitis
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 - Abivax S.A.See more
Urothelial cancer
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations - THOR CR108401 - Janssen Research & Development, LLCSee more
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy